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Summary To search for the signalling pathways in lung cancer relevant to its aggressive behaviour, we studied
tyrosine phosphorylated proteins in lung cancer cell lines and surgical specimens. We found that the profiles of
protein phosphorylation were closely matched among these cell lines and cancer tissues of different histological
origins, and 100 -130 kDa proteins were the major components of phosphorylated proteins. In surgical
specimens, approximately half of the cases showed tyrosine phosphorylation of these proteins in a tumour-
specific manner, and phosphorylation of these proteins showed good correlation with the survival length of
patients after operation. By immunoprecipitation with specific antibodies, we found that pl25FAK, p120 and ,B-
catenin were the major components of tyrosine-phosphorylated proteins in the surgical specimens. These results
suggest that tyrosine phosphorylation of these proteins may play a role in tumour relapse and is available as a
clinical marker.
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Despite the progress of modern combined therapy, prognosis
of lung cancer is extremely miserable among all malignancies.
To identify signalling pathways specific for tumour, tyrosine
kinases that showed tumour-specific expression have been
studied. Elevated expression of epidermal growth factor
(EGF) receptors (Cerny et al., 1986; Veale et al., 1987;
Dazzi et al., 1989; Berger et al., 1987; Haeder et al., 1988;
Siegfried, 1987) and c-erbB-2 genes (Kern et al., 1990;
Schneider et al., 1989; Weiner et al., 1990) in non-small-cell
lung cancer have been reported. Autocrine growth by insulin-
like growth factor I was observed in small-cell lung cancer
cells (Macaulay et al., 1988, 1990). However, tyrosine kinases
examined in these studies were limited to a few members of
receptor-type oncogenes, and signalling pathways in the
cancer tissues critical for tumorigenesis remain to be
identified.
To analyse the signalling through tyrosine phosphoryla-
tion in human cancer, we have studied phosphotyrosine
(pTyr)-containing proteins in various cancer cell lines with
anti-pTyr antibody (Hamaguchi et al., 1988; Takeshima et
al., 1991). To obtain more clues, we examined pTyr-
containing proteins in lung cancer tissues surgically resected
from patients. In this report, we show that roughly half the
cases of lung cancer tissues we examined have tyrosine
phosphorylation of 100- 130 kDa proteins and phosphoryla-
tion of these proteins, correlates with the survival time of the
patients. In addition, we show tyrosine phosphorylation of
p125FAK, p120 and XK-catenin in these surgical specimens.
These proteins were known as major components of the cell
adhesion system and their tyrosine phosphorylation showed
good correlation with transforming activity of v-Src kinase
(Schaller et al., 1992; Illic et al., 1995; Matsuyoshi et al.,
1992; Hamaguchi et al., 1988, 1993a; Illic et al., 1995;
Reynolds et al., 1989, 1992). Thus, tyrosine phosphorylation
of these proteins may perturb cell-cell adhesion and activate
tumour cell movement, invasion and metastasis.
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Materials and methods
Cells and tissues
All cell lines examined in this study were derived from human
lung cancer. QG-56, QG-90 and Darby were supplied by
Aichi Cancer Center (Kinjo et al., 1979). Luci-7, Luci-10 and
Luci-13 were donated by Memorial Sloan Kettering Cancer
Center. Histological origins of Luci-7, QG-56 and QG-90 are
large-cell carcinoma, squamous cell carcinoma and small-cell
carcinoma respectively. We have no data about the origin of
Luci-13 and Darby.
Tissue samples were obtained from surgical specimens of
44 patients diagnosed as lung cancer cases at the Nagoya
University Hospital. Small amounts of tissues resected were
frozen immediately with liquid nitrogen. Tumours were
classified according to the histological subgroups recom-
mended by the World Health Organization (WHO) and
staged by the tumour-nodal involvement-metastasis (TNM)
system.
Preparation ofanti-phosphotyrosine antibody and
immunoblotting
An affinity-purified antibody that specially recognised pTyr
residues was prepared as described previously (Hamaguchi et
al., 1988). To detect tyrosine phosphorylation of immuno-
precipitated proteins, peroxidase (PO)-conjugated anti-pTyr
antibody (Transduction Lab.) was used.
Cell lysates were prepared as described previously
(Takeshima et al., 1991). Frozen tissue samples were crushed
into fine pieces, suspended in a buffer containing 2% sodium
dodecyl sulphate (SDS) and 5% mercaptoethanol, and
immediately homogenised. Lysates were boiled and stocked
at -80°C until use.
Assay of protein concentration, SDS-7.5% polyacryla-
mide gel electrophoresis (PAGE) and immunoblotting with
anti-pTyr antibody were described previously (Hamaguchi et
al., 1988, 1993a).
Autoradiography was performed on an imaging plate for
bio-image analyser (Fuji), or by ECL chemiluminescence
system (Amersham).Tyrosine phosphorylation in lung cancer
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Immunoprecipitation
Immunoprecipitation was performed as described previously
(Hamaguchi et al., 1993b). Briefly, cells or crushed tissues
were suspended in RIPA buffer (10 mM Tris-HCl, pH 7.4,
150 mM sodium chloride, 1% Triton X-100, 1% deoxycholine
(DOC), 0.1% SDS, 0.5 mm sodium vanadate, 0.1 mm sodium
molybdate, 1% Trasylol and 1 mM phenylmethylsulphonyl
fluoride). The lysates were clarified by centrifugation and
incubated with antibody for 1 h at 4°C. Anti-p125FAK (UBI),
anti-p120, anti-o -catenin, anti-p-catenin, anti-pl30Cas (Trans-
duction Lab.) and anti-vinculin (Saga et al., 1985) antibodies
were used for the study. Immune complexes were recovered
by the addition of protein A-Sepharose beads (Pharmacia)
and subjected to PAGE.
Statistical analysis
Non-parametric statistical tests were used to evaluate all of
our studies. Chi-square test was used to assess the relation-
ship between categorical variables and the tyrosine phosphor-
ylation of 100- 130kDa proteins, and the Mann-Whitney
U-test was used to calculate P-values for continuous
variables. The relationship between the disease-free survival
time and clinicopathological variables was determined by
using the log-rank test, as described by Kaplan and Meier.
For multivariate analysis to confirm correlation of disease-
free survival time with other parameters, Cox's proportional
hazard model was used.
We next examined the tyrosine phosphorylation of
p125FAK in these cancer tissues. We could not examine all
the cases because of the shortness of tumour lysates, but
tyrosine phosphorylation of p125FAK was observed in two
cancer tissues in a tumour-specific manner (Figure 4, lanes C,
D, E and F). Although a protein band of 98 kDa was
detected in addition to pl25FAK (indicated by arrowheads), it
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Results
Tyrosine-phosphorylated proteins including pJ25FAK andp120
in lung cancer cells
Tyrosine-phosphorylated proteins in cell lines derived from
lung cancer and other cancers were examined by immuno-
blotting with anti-pTyr antibody. Rat cell line 3Y1 and 3Y1
transformed with src (SR3Y1) were used as a control. As
shown in Figure la, a subset of proteins of 100-130 kDa
was tyrosine phosphorylated in lung cancer cell lines of
different histological origins. Tyrosine phosphorylation of
similar proteins was widely observed in other cell lines
derived from oesophageal, gastric and colon cancer (Figure
lb). To assess the specificity of anti-pTyr antibody, we
examined the inhibitory effect of the phosphoamino acids
upon antibody-antigen recognition as previously described
(Takeshima et al., 1991). Addition of 5 mM pTyr to the anti-
pTyr antibody solution completely blocked the detection of
these proteins, indicating that these proteins were indeed
tyrosine phosphorylated (data not shown).
Since the major tyrosine-phosphorylated proteins ranged
from 100-130 kDa, we examined the phosphorylation of
p125FAK and p120. As shown in Figure 2, both p125FAK and
p120 were tyrosine phosphorylated and co-migrate with
major tyrosine-phosphorylated proteins in these cell lines.
Tyrosine-phosphorylated proteins including pJ25FAK in human
lung cancer tissues
We next examined pTyr-containing proteins in surgical
specimens. Of 44 lung cancer tissues examined, we found
tumour-specific elevation of tyrosine phosphorylation in 20
cases (Figure 3a), and the profiles of tyrosine-phosphorylated
proteins in these cases were similar irrespective of the
difference in histology. We found tyrosine phosphorylation
of a subset of proteins of 100-130 kDa that was similar to
those of cell lines. Another phosphorylated 50 kDa protein
band found in some cases could be a heavy chain of
immunoglobulin, since it was detected with ['25I]protein A
alone (data not shown).
A similar subset of pTyr-containing proteins was found in
the cancer tissues of other organs such as oesophageal cancer
and colon cancer (Figure 3b).
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Figure 1 Detection of tyrosine-phosphorylated proteins in
human lung cancer cell lines and other cell lines. Each cell
lysate (100,ug) was analysed for its tyrosine-phosphorylated
proteins by immunoblotting with anti-pTyr antibody. (a) Lung
cancer cells. (b) Oesophageal and gastric cancer cells. (c)
Colorectal cancer and control cells.Tyrosine phosphorylation in lung cancer
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Figure 2 Tyrosine phosphorylation of p125FAK and p120 in
human lung cancer cells. Tyrosine phosphorylation of pl25FAK
(a) and p120 (b) in human lung cancer cell lines, QG56 and
QG90, were examined by immunoprecipitating (IP) with anti-
p125FAK or anti-pl20 followed by immunoblotting (IB) with anti-
pTyr antibody. W, whole cell lysate; ppt, immunoprecipitated
fraction.
was detectable in samples immunoprecipitated without anti-
p125FAK (Figure 4, lanes A and B) but undetectable with PO-
conjugated anti-pTyr antibody (Figure 5a and c), suggesting
it to be a non-specific band detected by secondary antibody.
To confirm tyrosine phosphorylation of p125FAK, we
immunoprecipitated p125FAK repeatedly from the same
cancer tissue lysates and probed with anti-pTyr antibody
together with whole cell lysate and supernatant (Figure 5).
PO-conjugated anti-pTyr antibody was used in the following
experiments to avoid non-specific binding of secondary
antibody. Tyrosine phosphorylation of pl25FAK, which co-
migrated with one of the two major pTyr-containing proteins
was again clearly detected in tumour tissues of both cases and
decreased by repeated immunoprecipitation (Figure 5a and
c). Although repeated immunoprecipitation removed most of
the tyrosine-phosphorylated pl25FAK from the lysate (Figure
5a and b), the major pTyr-containing protein co-migrated
with pl25FAK remained in the supernatant fraction, suggest-
ing that there may be additional pTyr-containing proteins of
similar molecular size to p125FAK
To characterise other pTyr-containing proteins in cancer
tissues, we next immunoprecipitated p120, a- and fl-catenins,
p130Cas or vinculin. These proteins are well-known tyrosine-
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Figure 3 Tyrosine-phosphorylated proteins in surgical speci-
mens. Lysates from paired cancer (T) and normal (N) tissues were
analysed for tyrosine-phosphorylated proteins by immunoblotting
with anti-pTyr antibody. (a) lung cancer; (b), colorectal cancer
and oesophageal cancer. Cases 1-4, 6-7 and 9 in (a) showed
tyrosine phosphorylation of 100 -130kDa proteins, whereas cases
5 and 10 -12 did not.
phosphorylated proteins and have molecular sizes similar to
100-130 kDa phosphorylated proteins (Reynolds et al.,
1989; Hamaguchi et al., 1993a; Matsuyoshi et al., 1992;
Mayer et al., 1988; Sakai et al., 1994; Sefton et al., 1981).
Two tyrosine-phosphorylated protein bands were immuno-
a QG56 QG90Tyrosine phosphorylation in lung cancer
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Figure 4 Detection of pI25FAK phosphorylation in surgical specimens. p125FAK in lung cancer was immunoprecipitated with anti-
125FAK antibody and probed with anti-pTyr antibody as described in Materials and methods. A pair of normal (A) and cancer
tissue (B) was immunoprecipitated without anti-pl25 AK as a negative control. Normal (C and E) and cancer tissue (D and F)
obtained from cases 2 (C and D) and 9 (E and F) was immunoprecipitated with anti-pI25 AK antibody. (G) p125FAK from QG56
cells as a control.
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Figure 5 Tyrosine phosphorylation of p125FAK and p120 in surgical specimens. Lysates of cancer tissues were repeatedly
immuno recipitated with anti-p 25FAK (a, b and c) or anti-p 120 (d and e) and subsequently probed with anti-pTyr (a, c and d), anti-
p125FA (b) or anti-p 120 (e). a, b, d and e, case 2; c, case 9. Lane 1, whole cell lysate; lane 2, first immunoprecipitated sample; lane
3, second immunoprecipitated sample; lane 4, supernatant of immunoprecipitation.
precipitated with anti-p120 antibody (Figure 5d and e),
suggesting p120 as one of the major pTyr-containing proteins
in cancer tissue. Tyrosine phosphorylation of a- and f,-
catenins was examined. Expression of a-catenin was low and
its tyrosine phosphorylation was undetectable (Figure 6a and
b). ,B-catenin was clearly tyrosine phosphorylated and co-
migrated with a faint band below the two major pTyr-
containing proteins of cancer tissues (Figure 6c and d). A
pTyr-containing protein slightly larger than ,B-catenin was co-
immunoprecipitated with f,-catenin (Figure 6c). We could not
identify protein species of this band. In addiiton to the results
with case 2, we found tyrosine phosphorylation of p120 and
/3-catenin in another case (case 9). Tyrosine phosphorylation
of vinculin and p130Cas was next examined. We could not
detect phosphorylation of vinculin (Figure 7a and b). Since
anti-p 30Cas antibody was available only for immunoblotting,
we immunoprecipitated pTyr-containing proteins from tissue
lysate by anti-pTyr antibody and subsequently probed with
anti-p 30Cas antibody together with whole cell lysate and
supernatant (Figure 7c and d). Although a faint band
migrating slower than p130Cas was detected in immunopreci-
pitated fraction (Figure 7d, lane 2*), most of p130'S
remained in the supernatant (Figure 7d, lane 3), suggesting
p130cas is not the major pTyr-containing protein of lung
cancer tissue.
We examined expression of EGF receptor and c-erbB-2
protein in these cancer tissues. All tumour tissues examined
expressed EGF receptor to similar levels, but only two cases
expressed c-erbB-2 in a tumour-specific manner and these
cases were both adenocarcinoma with mediastinal node
metastasis (data not shown).
Association of 100- 130 kDa proteins' phosphorylation with
clinicopathological manifestations
Tables I and II are the summary of clinicopathological
manifestations in the cases we examined. These objectives
consisted of 19 squamous cell, 23 adeno, 1 adenosquamous
- p120
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Figure 6 Tyrosine phosphorylation of catenins in surgical specimens. Lysates of cancer tissues (case 2) were repeatedly
immunoprecipitated with anti-a-catenin (a and b) or anti-,B-catenin (c and d) and probed with anti-pTyr (a and c) anti-oc-catenin (b)
or anti-,B-catenin (d). Lane 1, whole cell lysate; lane 2, first immunoprecipitated sample; lane 3, second immunoprecipitated sample;
lane 4, supernatant of immunoprecipitation.
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Figure 7 Detection of vinculin and pl 30Cas in surgical specimens. Lysates of cancer tissues (case 2) were immunoprecipitated with
anti-vinculin (a and b) or anti-pTyr (c and d) antibody and probed with anti-pTyr (a and c), anti-vinculin (b) or anti-pl30C'S (d)
antibody. Lane 1, whole cell lysate; lane 2, first immunoprecipitated sample; lane 3, in a, second immunoprecipitated sample; lane 3,
in c and d, supernatants; lane 4 in a, supernatant of immunoprecipitation.
and 1 small-cell carcinoma, and were obtained from 33 male
and 11 female patients with an age range of 49 to 78 years
(average 65 years). We found that 20 cancer tissues (45% of
those examined) showed tumour-specific phosphorylation of
100-130 kDa proteins (Table I). Tyrosine phosphorylation
of these proteins was found in 47% (9 of 19 cases) of
squamous cell carcinoma tissues and 43% (10 of 23 cases) of
adenocarcinoma tissues. Tyrosine phosphorylation of these
proteins was not associated with age (P = 0.54), sex (P = 0.29),
the histological classification (P= 0.55), the tumour size
(P=0.95), or pathological T factor of TNM classification
(P=0.10) (Table I). However, we found that the cases with
nodal involvement (NI and N2) had clearly higher incidence
of tyrosine phosphorylation of these proteins compared with
those with no nodal involvement (NO) (P=0.01) (Table I). In
addition, cases which showed tyrosine phosphorylation had a
shorter survival length after operation compared with those
without tyrosine phosphorylation (P=0.01). To extend these
observations, we next examined the relationship between
clinicopathological variables and disease-free survival time
(Table II). Because of short post-operative follow-up time,
most of the factors did not affect survival time of patients
except for the protein phosphorylation of 100- 130 kDa
proteins (P= 0.01) and p-N factor (P= 0.03). Surprisingly,
three of eight pathological TINO cases phosphorylating 100-
130 kDa proteins relapsed in one year after operation. To
confirm further, correlation of disease-free survival time with
phosphorylation of 100-130 kDa proteins and nodal
involvement was examined by Cox's proportional hazard
model. Correlation of survival length with tyrosine phos-
P-catenin
P-catenin
b CA*
CASTyrosine phosphorylation in lung cancer
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Table 1 Tyrosine phosphorylation of 100- 130kDa proteins and clinicopathological variables
for patients with human lung cancer
Phosphorylation of 100-130kDa proteins
Negative Positive
(n =24) (n =20) P-valuea
Male
Female
Primary tumour
1
2
3
4
Regional lymph nodes
0
1
2
Metastasis
0
1
16
8
8
9
6
1
22
1
1
24
0
17
3
10
6
3
8
S
7
20
0
0.29
0.10
0.001
Surgical stage
1 17 6
2 0 4
3A 6 7 0.02
3B 1 3
Histology
Adenocarcinoma 13 10
Squamous cell carcinoma 10 9
Adenosquamous carcinoma 1 0 0.55
Small-cell carcinoma 0 1
Continuous variables
Age (years) 65.4±7.7b 64.3 7.4 0.54
Tumour size (cm) 3.8 +1.9 3.7+ 1.6 0.95
Survival (days) 928.0+74.6 316.8+33.8 0.01
aP-values calculated using Fisher's exact test and Mann-Whitney U-test. The value for
survival was calculated using the log-rank test as determined by Kaplan and Meier. bMean ± s.d.
phorylation of 100- 130 kDa proteins was statistically
significant (P =0.03), although survival length showed poor
correlation with nodal involvement (P =0.16). The cumula-
tive probability of disease-free survival is displayed in Figure
8 for p-stage of TNM and Figure 9 for 100-130 kDa
proteins' phosphorylation. These results strongly suggested
that the tyrosine phosphorylation of 100-130 kDa proteins,
probably including pl25FAK, p120 and fJ-catenin, correlates
with a malignant phenotype of lung cancer.
Discussion
Evidence has been accumulated that oncogenes that encode
tyrosine kinases are involved in tumorigenesis of human
cancer. The results presented in this report demonstrate that,
in lung cancer tissues, a subset of 100- 130 kDa proteins was
indeed tyrosine phosphorylated in a tumour-specific manner.
Of 44 cases of lung cancer we examined, 20 cases showed
tyrosine phosphorylation of these proteins. We found that the
profiles of phosphorylation in cancer tissues resembled each
other and similar phosphorylated proteins were also found in
oesophageal and colorectal cancer tissues, despite the
difference in histological types and origins of cancer. In
addition, statistical analysis showed good correlation of these
protein phosphorylations with poor prognosis of patients.
These results suggest that signalling via tyrosine phosphor-
ylation of these proteins may play an important role in
tumorigenesis.
By histochemical analysis, amplification of EGF receptor
(Cerny et al., 1986; Veale et al., 1987; Dazzi et al., 1989;
Berger et al., 1987; Haeder et al., 1989; Siegfried, 1987) and
c-erbB-2 (Kern et al., 1990; Schneider et al., 1989; Weiner et
al., 1990) in human lung cancer tissues has been reported.
However, we found no clear correlation between the levels of
EGF receptor of c-erbB-2 expression and the levels of
tyrosine phosphorylation in cancer tissues (data not shown).
Moreover, neither tyrosine-phosphorylated proteins corre-
Table II Disease-free survival and clinicopathological variables for
patients with human lung cancer
Survival (days) P-valuea
Sex
Male (31) 780.6 ±79.8b
Female (10) 346.7±48.3 0.50
Primary tumour
1 (8) 1069.0 +0
2 (17) 369.4+34.0 0.07
3 (12) 370.5+29.6
4 (4) 408.0+193.5
Regional lymph nodes
0 (28) 844.2+ 79.9
1 (6) 736.2± 182.3 0.002
2 (7) 244.7+42.6
Surgical stage
1 (21) 818.1±95.3
2 (4) 313.0+ 90.1
3A (12) 370.5+29.6 0.16
3B (4) 408.0+ 193.5
Histology
Adenocarcinoma (21) 550.3+ 107.4
Squamous cell carcinoma (18) 899.8 ±82.0
Adenosquamous carcinoma (1) 368.0+0 0.11
Small-cell carcinoma (1) 359.0+ 0
100 -130kDa proteins
phosphorylation
Negative (22) 928.0+ 74.6
Positive (19) 316.8+ 33.8 0.01
aP-value for disease-free survival was calculated using the log-rank
test as determined by Kaplan and Meier. bMean+ s.d.
sponding to autophosphorylated EGF receptor nor that of c-
erbB-2 protein were found in cancer tissues. These results
suggest that other kinases in addition to EGF receptor and c-
erbB-2 may be required for the phosphorylation of 100-
130 kDa proteins.Tyrmm psuphu
inkm camce
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Fugwe 9 Disease-free survival curve of all patients with or
without tyrosine phosphorylation of 100-130kDa proteins. The
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distribution for each subgroup. The log-rankr test was used to
evaluate the equality of the survival curves.
By immunoprecipitation with specific antibodies, we found
tyrosine phosphorylation of pl25F', p120 and -catenin in
lung cancer tissues. Attention has been drawn to pl25F' by
its unique structure and character (Schaller et al., 1992). This
kinase was found as a major pTyr-containing protein in
RSV-transformed cells and appeared to localise to focal
adhesions. Recent studies suggest that pl25FA' kinase is
involved in multifanous cellular functions such as cell
adhesion (Kornberg et al., 1992), shape (Burridge et al.,
1992), motility and growth (Zachary et al., 1992) as well as
transformation. Targeting ofpl25F gene in mice resulted in
a defect of mesoderm development, and cells from these
embryos had reduced mobility in vitro (Illic et al., 1995).
pl25F' becomes tyrosine phosphorylated and activated in
response to integrin-mediated binding of cells to the
extracellular matrix, suggesting pl25FAK phosphorylation is
important for cell adhesion and/or migration (Kornberg et
al., 1992; Burridge et al., 1992). f-catenin is one of the
components of the cadherin-catenin cell adhesion system
and appears to play a crucial role in cadherin-dependent cell
adhesion. In the huiman gastric cancer cell line, HSC-39,
mutation in the f-catenin gene that resulted in complete
abolishment of E-cadherin-dependent cell-cell adhesion was
observed, and transfection of the f-ctenin gene in the cells
fully recovered the cell-cell adhesion (Kawanishi et al.,
1995). We have previously reported (Matsuyoshi et al., 1992;
Hamaguchi et al., 1993a) that cadherin dependent cell-cell
adhesion was strongly erturbed upon tyrosine phosphoryla-
tion of f-catenin in RSV-transformed cells where cadherins
and catenins were expressed and formed complexes as normal
cells. Another pTyr-containing protein, pl20, was also
identified as a major pTyr-containing protein in RSV-
transformed cells whose phosphorylation closely correlated
with cell transformation (Reynolds et al., 1989). Later study
showed that pl20 had close homology with a group of cell
adhesion molecules, -catenin, plakoglobin and armadillo
(Reynolds et al., 1992), suggesting that p120 may also play a
role in cell adhesion. Thus, tyrosine phosphorylation of these
adhesion molcules may result in suppression of cell-cell
adhesion and activated lung cancer cell migration, invasion
and metastasis.
Besides p125FAK, 120 and f-catenin, other tyrosine-
phosphorylated proteins ranged 100-130 kDa were found
in cancer tissue. At present, we do not know precisely how
many and what kind ofproteins are included. These tyrosine-
phosphorylated proteins included neither pl30cP, w-catenin
nor vinculin. We found, however, that this subset oftyrosine-
phosphorylated proteins was found in various types of
human cancer cell lines (Figure 1) and in the cancer tissues
of other organs (Figure 3). Further characterisation of the
species of the tyrosine-phosphorylated proteins is an
important problem to be studied.
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